SAVING LIVES FROM WITHIN BY PROTECTING CELLS
Saving lives threatened by untreatable diseases of major organs, including the liver, kidneys, heart and brain, by using our unique patented technology to directly block programmed cell death.
SeaBeLife is a biotechnology company developing two families of patented candidate molecules designed to block regulated necrosis – also known as regulated cell death.
Our therapeutic solution has demonstrated, in vitro and in multiple in vivo proofs-of-concept, to be able to simultaneously block two forms of regulated cell death and thus protect organs under attack from disease.
Founded in 2019, SeaBeLife is a biotechnology company that develops innovative small molecules that simultaneously target two major regulated cell death pathways -necroptosis and ferroptosis – designed to address major unmet medical needs in acute, rare and chronic indications.
This first-in-class approach is unique: to date, no dual inhibitor of these two pathways is available on the market.
Indications
SeaBeLife focuses on severe acute and chronic pathologies, with single or short courses of treatment and high, unmet medical needs.
Its most advanced program targets dry AMD, a common retinal degenerative disease with no effective, well-tolerated treatment. This will also help validate the unique treatment developed by the company.
SeaBeLife is also developing its program in acute and orphan pathologies, such as severe acute hepatitis.
In the longer term, SeaBeLife aims to extend its indications to acute renal failure, heart failure, stroke and certain neurodegenerative diseases.
Targeting diseases that currently lack available therapeutic alternatives
gateway indications
Age-related macular degeneration (AMD)
In developed countries, the severe form of dry AMD, geographic atrophy, is the leading cause of visual impairment in people over 50. There is no effective treatment to limit progressive and irreversible vision loss. Our aim is to directly protect retinal pigment epithelium cells and photoreceptors to prevent vision loss. Our SBL03 candidate, formulated as a topical non-invasive solution (such as an eye-drop for the patient), has shown very promising in vivo results by directly targeting retinal cell necrosis to slow the progression of geographic atrophy.
https://www.seabelife.com/wp-content/uploads/2025/06/Article-pre-serie-A-2025_EN.pdf
Acute hepatitis and fulminant hepatitis
Severe hepatitis is the sudden, massive damage to the liver that can be caused by drug intoxication, viral infection or autoimmune hepatitis. Despite a high mortality rate of 30%, currently the only effective treatment for these very serious pathologies is liver transplantation. SeaBeLife’s approach is to inhibit regulated deleterious cell death pathways in order to combat these liver disorders directly, by protecting the cells, whatever the cause, in order to save lives, reduce the need for transplants and shorten stays in intensive care.
moonshots
Parkinson’s disease
Parkinson's Disease (PD), a common neurodegenerative disease with no known treatment, affects more than 8 million people worldwide. It is characterized by the loss of dopaminergic neurons, specifically by autophagy. Blocking regulated cell necrosis could prevent this upstream phenomenon and protect neurons, halting the progression of the disease.
Acute Renal Failure (ARF), myocardial infarctions, strokes
These severe diseases cause traumatic injury to an individual’s vital organs, with very few effective therapeutic treatments available. Once our therapeutic approach has been validated in severe hepatitis, our aim is to extend our technology to the treatment of these acute pathologies.
Other neurodegenerative diseases
Regulated necrosis is also involved in several other neurodegenerative diseases: Alzheimer’s disease, Amyotrophic Lateral Sclerosis, Huntington's disease, Niemann-Pick, Gaucher’s disease etc.
Technology
Fighting regulated necrosis
When a cell dies, several mechanisms can come into play. In some cases, two regulated forms of necrosis — necroptosis and ferroptosis — are activated in a coordinated and mutually reinforcing way. These two processes begin to interact, switching from one to the other, which amplifies the damage by triggering a cascade of cell death in neighboring tissues.
This vicious cycle contributes to inflammation and oxidative stress, both of which are highly detrimental to surrounding cells and organs. As a result, the activation of necroptosis and ferroptosis is not only harmful locally, but can also worsen the overall prognosis of the associated disease
A UNIQUE MECHANISM OF ACTION TO DEVELOP ‘FIRST IN CLASS’ DRUGS
These regulated forms of necrosis communicate with each other, one leading to the other, or one taking over from the other in the event of inhibition of only one of the pathways.
This means that, when dealing with these forms of regulated necroses, it is essential that both are blocked at the same time.
The unique characteristic in all the molecules developed by SeaBeLife is that they fight necroptosis and ferroptosis simultaneously.
IN VIVO TESTED MOLECULES
The molecules developed by SeaBeLife are the result of more than 10 years of research and screening of large collections of molecules, in particular those from the Roscoff Biological Station in Brittany, France.
Two families of molecules have been optimized thanks to the bespoke technological platform developed by SeaBeLife, leading to a unique collection of ferroptosis/necroptosis inhibitors protected by six patent families.
These molecules have demonstrated, both in vitro and in several in vivo models, their ability to simultaneously block two forms of regulated cell death and thus to protect the organs under attack.
In particular, we have obtained proof of efficacy in several mouse models of hepatotoxicity, renal failure and ocular pathologies. The compounds have also been very well tolerated.
Pipeline / indication
in cellulo
POC
in vivo
POC
Regulatory
Preclinic
Regulatory
Preclinic
SBL#1 - IntraVenous (IV)
Acute liver injury (ALI) / Acute liver failure (AHI) - Orphan diseases
SBL#3 - intravitreal injection with ophthalmic gel/instillation
Macular degeneration (POC in dry AMD and Stargardt's disease - orphan disease)
SBL#OXs – Drug Discovery in progress
Neurodegenerative diseases
